Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

BACKGROUND: A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV(1)) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in symptomatic patients with chronic obstructive pulmonary di...

Descripción completa

Detalles Bibliográficos
Autores principales: Driessen, M. T., Whalen, J., Seewoodharry Buguth, B., Vallejo-Aparicio, L. A., Naya, I. P., Asukai, Y., Alcázar-Navarrete, B., Miravitlles, M., García-Río, F., Risebrough, N. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245710/
https://www.ncbi.nlm.nih.gov/pubmed/30458866
http://dx.doi.org/10.1186/s12931-018-0916-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245710/
https://www.ncbi.nlm.nih.gov/pubmed/30458866
http://dx.doi.org/10.1186/s12931-018-0916-7

Ejemplares similares